Abata Therapeutics engineers Treg cell therapies to target antigens present in tissue where an autoimmune response has been triggered, enabling patients to maintain a stable and stimulates tissue residency. The company's approach stops immune-mediated destruction, restores homeostasis, and promotes repair in affected tissues. Abata has early programs in Type 1 Diabetes and inclusion body myositis, and brings together industry experts and pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. The company aims for a transformative impact on people's lives.